Recombinant activated factor VII (rFVIIa; NovoSeven) has been widely used to treat bleeding in patients with haemophilia with inhibitors. To increase the intrinsic activity, analogues of rFVIIa (rFVIIa Q, rFVIIa DVQ, and rFVIIa DVQA) with altered amino acid sequence at or near the active centre have been developed. The immunogenicity of these analogues was tested in a rat immune tolerance model...

This study examined dose-response relationships between activated recombinant factor VII (rFVIIa) and (1) in vivo haemostasis and (2) in vitro measures of coagulation and platelet function. Anesthetized swine were used. Ear bleeding time (BT) was measured and blood was sampled following increasing doses of rFVIIa (0, 90, 180, 360 and 720 microg/kg; n=6) or saline (n=6). BT was not altered by rF...

BACKGROUND Complex cardiovascular surgery often results in postoperative hemorrhage. Excessive blood product use may cause systemic thrombosis, end-organ dysfunction, and edema preventing chest closure. Recombinant activated factor VII (rFVIIa) concentrate may decrease hemorrhage where other treatment measures failed. We reviewed our experience with rFVIIa after complex cardiovascular surgery. ...

BACKGROUND The purpose of this study was to determine the role of recombinant activated factor VII (rFVIIa) in abdominal, vascular, and urological surgery. METHODS We conducted meta-analyses of case series and placebo-controlled studies reporting on the treatment or prophylaxis of bleeding with rFVIIa regarding 'reduction or cessation of bleeding', 'mortality', and 'thromboembolism'. RESULT...

PURPOSE There are an increasing number of anecdotal reports and trials of recombinant activated factor VII (rFVIIa) for bleeding during surgery. The reports of rFVIIa during cardiac surgery are limited. We report our experience using rFVIIa, in the operating room; to treat bleeding that prevented chest closure, despite appropriate conventional treatment, following complex cardiac surgery. MET...

OBJECTIVE Recombinant factor VIIa (rFVIIa, NovoSeven) has proven efficacy in treating bleeding in hemophilia patients with inhibitors. A rFVIIa analog with mutations V158D/E296V/M298Q (NN1731) exhibits increased procoagulant activity in in vitro and in vivo models. The aim of this work was to define the effects of NN1731 toward factor X activation, platelet activation, thrombin generation, and ...

血友病インヒビター患者の止血管理にバイパス止血剤が併用されるが確立された療法はない．今回，活性化第VII/第X因子（FVIIa/FX）および高用量組換え（r）FVIIaの併用療法を施行した血友病Bインヒビター患者1例の凝固能を評価した．止血困難な出血時にFVIIa/FX，高用量rFVIIaの順で投与したところ，FVIIa/FXまたは高用量rFVIIaの投与前後でAPTTは短縮し，トロンビン産生およびFVII抗原量は増加した．一方，FX抗原量はFVIIa/FXの投与前後でのみ増加した．また，高用量rFVIIa単独投与に比して，FVIIa/FX投与翌日の高用量rFVIIa追加投与後の凝固能は強まった．併用療法に際して過凝固の徴候は見られなかった．FVIIa/FX投与による高濃度FX存在下でのrFVIIa追加投与は，血友病Bインヒビターの難治性出血に対する合理的な止血戦略となり得る可能性が...

PURPOSE The purpose of this study was to investigate the role of low-dose recombinant factor VIIa (rFVIIa) (20 μg/kg) in reversing coagulopathy in patients with isolated traumatic brain injury (TBI). MATERIALS AND METHODS Patients with isolated TBI and coagulopathy at admission were enrolled prospectively from January 2010 to December 2011. The patients were divided into 2 groups: the rFVIIa ...

OBJECTIVES We evaluated the efficacy and safety of recombinant activated factor VII (rFVIIa) in children aged < 18 years old with grade II or grade III Dengue hemorrhagic fever (DHF) who required blood component therapy for controlling bleeding episodes. STUDY DESIGN Patients were randomized to the rFVIIa group or placebo group in a ratio of 2:1. rFVIIa or placebo (100 microg/kg body weight) ...

BACKGROUND The majority of patients with potentially survivable combat-related injuries die from hemorrhage. Our objective was to determine whether the use of recombinant activated factor VII (rFVIIa) decreased mortality in combat casualties with severe trauma who received massive transfusions and if its use was associated with increased severe thrombotic events. METHODS We retrospectively re...